Literature DB >> 33429825

Clinical application of next-generation sequencing for the management of desmoid tumors: A case report and literature review.

Jeong Mi Lee1,2, Han Gyeol Kim1,3, So Youn Shin4, Seung Hyeun Lee2.   

Abstract

RATIONALE: Desmoid tumors are rare myofibroblastic neoplasms characterized by local invasiveness and high rates of recurrence, and sometimes mimic local recurrence of previously resected malignancies. Previous studies have suggested that molecular profiling may be useful for the diagnosis of the tumors and risk stratification. However, the clinical utility of next-generation sequencing (NGS) for the management of desmoid tumors has not been established. PATIENT CONCERNS: A 42-year-old man visited our clinic for routine follow-up 1 year after left upper lobe lingular segmentectomy for lung adenocarcinoma. DIAGNOSES: Chest computed tomography showed a pleural mass adherent to the thoracotomy site. Positron emission tomography revealed mildly increased metabolism with a maximal standardized uptake value of 2.7 within the tumor, suggesting local recurrence of the previous neoplasm. Exploratory thoracotomy and en bloc resection of the tumor revealed spindle cells in a massive collagenous tissue consistent with a desmoid tumor.
INTERVENTIONS: NGS was performed to confirm the diagnosis and to identify any genetic alterations that might be relevant to the prognosis of this tumor. The tumor harbored an S45F mutation in CTNNB1, which has been correlated with a high recurrence rate. Therefore, we performed adjuvant radiotherapy on the resection bed at a dose of 56 Gy. OUTCOMES: The patients experienced no postoperative or radiotherapy-related complications. Periodic follow-up examinations using computed tomography were performed every 3 months, and no evidence of recurrence of either tumor was observed during the 38 months after the last surgery. LESSONS: To the best of our knowledge, this is the first case reporting the clinical application of NGS and aggressive treatment based on the genotyping results for the management of a desmoid tumor. Our case highlights the need to consider desmoid tumors among the differential diagnoses when a pleural mass is encountered at a previous thoracotomy site. More importantly, molecular profiling using NGS can be useful for the establishment of a treatment strategy for this tumor, although further investigations are required.
Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33429825      PMCID: PMC7793316          DOI: 10.1097/MD.0000000000024238

Source DB:  PubMed          Journal:  Medicine (Baltimore)        ISSN: 0025-7974            Impact factor:   1.817


  29 in total

1.  Cytogenetic, clinical, and morphologic correlations in 78 cases of fibromatosis: a report from the CHAMP Study Group. CHromosomes And Morphology.

Authors:  I De Wever; P Dal Cin; C D Fletcher; N Mandahl; F Mertens; F Mitelman; J Rosai; A Rydholm; R Sciot; G Tallini; H Van Den Berghe; R Vanni; H Willén
Journal:  Mod Pathol       Date:  2000-10       Impact factor: 7.842

2.  Gene Expression Profiling of Desmoid Tumors by cDNA Microarrays and Correlation with Progression-Free Survival.

Authors:  Sébastien Salas; Celine Brulard; Philippe Terrier; Dominique Ranchere-Vince; Agnes Neuville; Louis Guillou; Marick Lae; Agnes Leroux; Olivier Verola; Kurtz Jean-Emmanuel; Sylvie Bonvalot; Jean-Yves Blay; Axel Le Cesne; Alain Aurias; Jean-Michel Coindre; Frederic Chibon
Journal:  Clin Cancer Res       Date:  2015-04-15       Impact factor: 12.531

3.  Intrathoracic desmoid at previous thoracotomy site.

Authors:  P E Giustra; H O White; P J Killoran
Journal:  J Can Assoc Radiol       Date:  1979-06

4.  Desmoid-type chest wall fibromatosis. A six cases series.

Authors:  A Zehani-Kassar; A Ayadi-Kaddour; A Marghli; I Ridene; H Daghfous; T Kilani; F El Mezni
Journal:  Orthop Traumatol Surg Res       Date:  2011-01-15       Impact factor: 2.256

5.  Increased midkine expression correlates with desmoid tumour recurrence: a potential biomarker and therapeutic target.

Authors:  Chiara Colombo; Chad J Creighton; Markus P Ghadimi; Svetlana Bolshakov; Carla L Warneke; Yiqun Zhang; Kristelle Lusby; Shirley Zhu; Alexander J Lazar; Robert B West; Matt van de Rijn; Dina Lev
Journal:  J Pathol       Date:  2011-08-08       Impact factor: 7.996

6.  Desmoid tumor of the chest wall following chest surgery: report of a case.

Authors:  J Shimizu; Y Kawaura; Y Tatsuzawa; K Maeda; M Oda; A Kawashima
Journal:  Surg Today       Date:  1999       Impact factor: 2.549

7.  Desmoid tumour in thoracotomy scar 5 years after excision of a left giant atrial appendage aneurysm in female with a family history of Gardner's syndrome.

Authors:  M T Mole; P Goldstraw; M N Sheppard
Journal:  Thorac Cardiovasc Surg       Date:  1992-10       Impact factor: 1.827

8.  Expression of beta-catenin and p53 are prognostic factors in deep aggressive fibromatosis.

Authors:  C Gebert; J Hardes; C Kersting; C August; H Supper; W Winkelmann; H Buerger; G Gosheger
Journal:  Histopathology       Date:  2007-03       Impact factor: 5.087

9.  Prognostic factors for extra-abdominal and abdominal wall desmoids: a 20-year experience at a single institution.

Authors:  Kai Huang; Hong Fu; Ying-Qiang Shi; Ye Zhou; Chun-Yan Du
Journal:  J Surg Oncol       Date:  2009-12-01       Impact factor: 3.454

10.  Mutations of adenomatous polyposis coli (APC) gene are uncommon in sporadic desmoid tumours.

Authors:  M Giarola; D Wells; P Mondini; S Pilotti; P Sala; A Azzarelli; L Bertario; M A Pierotti; J D Delhanty; P Radice
Journal:  Br J Cancer       Date:  1998-09       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.